Quantum BioPharma Ltd.
QNTMHealthcare|Biotechnology|CA
$2.10
-0.01 (-0.24%)
DCF Value
$0.09
Tangible Book / Share
$0.27
Cash / Share
$1.46
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05652907 Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) | Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic | P2 | Terminated | 2 | RCT, Double-blind | FSD201, Placebo |
| NCT04619706 Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19 | COVID-19 | P2 | Terminated | 53 | RCT, Double-blind | FSD201, Placebo |
| NCT06595706 Evaluating the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adult Participants | Heathy Participants | P1 | Completed | 16 | Double-blind | Lucid-21-302, Placebo |
| NCT05821387 Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers | Healthy Participants | P1 | Completed | 40 | RCT, Double-blind | Lucid-21-302, Placebo |
| NCT06505239 Assessing the Safety and Efficacy of FSD-F2R6-A-CP in Volunteers in an Induced State of Alcohol Intoxication | Acute Alcohol Intoxication | N/A | Completed | 26 | RCT, Double-blind | — |